Diets · Metabolic & Cardiometabolic
low LDL cholesterol decreases subclinical atherosclerosis
In plain terms: If your LDL is very low, are you safe from artery plaque?
No — a large imaging cohort found plaque in a substantial share of people even with LDL under 70, so very low LDL lowers but does not eliminate subclinical atherosclerosis (residual risk).
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Optimal LDL does NOT guarantee absence of plaque: in PESA, subclinical atherosclerosis was present in a large fraction of people with optimal LDL and no risk factors. This supports the honest point (which Norwitz pushes hard) that LDL is necessary-but-not-sufficient - while remaining fully compatible with LDL being causal and worth lowering.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Georgakis 2022 2022 · J Am Heart Assoc | observational | supports | moderate | [FT-verified] UKB factorial MR n=408225 additive LDL-lowering benefit confirmed FT |
| Mendieta 2023 · J Am Coll Cardiol | observational | mixed | moderate | PESA 6y: LDL-C a key determinant of atherosclerosis progression AND regression — low/lowered LDL favors regression (supports LDL-lowering) yet baseline plaque exists at low LDL (residual). Net: compatible. |
| Wang 2022 · Circ Cardiovasc Qual Outcomes | meta-analysis | supports | high | Meta-analysis: each mmol/L LDL reduction compounds over time; longer exposure yields greater event/atherosclerosis risk reduction. |
| Grobbee 2004 · Cardiology | observational | supports | moderate | Vascular-imaging review: statin LDL lowering slows progression and promotes regression of subclinical atherosclerosis (CIMT/IVUS). |
| Dalakoti M 2025 · Singapore Med J | observational | supports | low | Review: risk-factor levels conventionally considered safe, including LDL-C, may still permit subclinical atherosclerosis - a nuance that low LDL reduces but does not abolish subclinical burden. |
| Fernandez-Friera L, et al. (PESA) 2017 · J Am Coll Cardiol | observational | supports | moderate | [FT-verified] pesa-2017 PESA n=1779 CVRF-free 49.7% plaque LDL OR 1.14-1.18/10mg (DUP of pesa-2017) ⚠️ correction-on-file (Crossref) - kept, corrigendum not retraction |
| Raposeiras-Roubin 2021 · J Am Coll Cardiol | observational | tested-null | moderate | PESA: even with LDL-C below guideline thresholds, higher triglycerides linked to more subclinical atherosclerosis/vascular inflammation — residual atherosclerotic risk at low LDL. |
| Di Giacomo Barbagallo 2025 · Cardiovasc Diabetol | observational | mixed | moderate | FH subjects: subclinical atherosclerosis tracked LDL burden but genotype modified glycemic/atherosclerotic injury; LDL not sole determinant. |
| Mancini 2018 · Can J Cardiol | observational | supports | moderate | Convergent RCT/MR/registry evidence: very low LDL is safe, regresses/stabilizes atherosclerosis; supports early lowering. |
| Nicholls 2018 · J Am Coll Cardiol | RCT | supports | high | Evolocumab-driven LDL lowering shifted coronary plaque composition favorably in statin-treated patients (GLAGOV substudy). |
| Ference 2012 2012 · J Am Coll Cardiol | observational | supports | high | [FT-verified] MR meta 9 SNPs ~3x CHD reduction for lifelong-lower LDL |
| Ference 2017 · European Heart Journal | observational | supports | high | EAS consensus integrating genetic/epidemiologic/RCT evidence: LDL causally drives ASCVD; lower lifetime LDL means less atherosclerosis, dose-dependent. |
| Ueki 2024 · J Atheroscler Thromb | observational | supports | moderate | Imaging review: LDL lowering with statin+ezetimibe+PCSK9i consistently reduces coronary plaque burden and improves composition. |
| Faridi KF 2024 · JACC Adv | observational | supports | moderate | Miami Heart Study, 1,033 low-risk adults: coronary atherosclerosis prevalence rose stepwise with LDL-C (13.2% at LDL <70 mg/dL, increasing at higher LDL) - lower LDL tracks less subclinical coronary disease. |
| Nicholls 2016 · JAMA | RCT | supports | high | GLAGOV: adding evolocumab to statins lowered LDL and regressed coronary atheroma volume by IVUS vs statin alone. |
| Oliver 2023 · Curr Atheroscler Rep | RCT | supports | high | IMPROVE-IT: ezetimibe added to statin further lowered LDL and reduced cardiovascular events after ACS ('even lower is even better'). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.